Victory Square Technologies Reports 2024 Achievements and Outlines 2025 Strategic Vision
Victory Square Technologies reported significant achievements for 2024 and outlined its 2025 strategic vision. The company achieved $10.7M in Q3 net income and reported an unaudited Net Asset Value of $127.5M as of January 28, 2025. Their subsidiary Hydreight Technologies ranked #56 on the 2024 Deloitte Technology Fast 500, achieved profitability, and launched a $10M Health Accelerator program.
The company's VSDHOne platform now powers healthcare brands across all 50 U.S. states, offering telehealth and compliance solutions. Key developments include Insu Therapeutics' work on oral insulin delivery technology, Stardust Solar's expansion into Houston with a $1.2M raise, and EdgeTI's advancement in quantum computing applications.
The company's portfolio has grown from $4M in 2017 to approximately $127M today, with investments totaling $13M across 25 companies selected from over 1,000 evaluated.
Victory Square Technologies ha riportato risultati significativi per il 2024 e ha delineato la sua visione strategica per il 2025. L'azienda ha raggiunto $10,7M di utile netto nel Q3 e ha registrato un Valore Netto degli Attivi non verificato di $127,5M al 28 gennaio 2025. La loro sussidiaria Hydreight Technologies si 猫 classificata al #56 nella lista 2024 Deloitte Technology Fast 500, ha raggiunto la redditivit脿 e ha lanciato un programma di Salute Accelerata da $10M.
La piattaforma VSDHOne dell'azienda ora supporta marchi di assistenza sanitaria in tutti i 50 stati degli Stati Uniti, offrendo soluzioni di telemedicina e conformit脿. Sviluppi chiave includono il lavoro di Insu Therapeutics sulla tecnologia di consegna di insulina orale, l'espansione di Stardust Solar a Houston con una raccolta da $1,2M e i progressi di EdgeTI nelle applicazioni di calcolo quantistico.
Il portafoglio dell'azienda 猫 cresciuto da $4M nel 2017 a circa $127M oggi, con investimenti totali di $13M in 25 aziende selezionate da oltre 1.000 valutate.
Victory Square Technologies inform贸 logros significativos para 2024 y deline贸 su visi贸n estrat茅gica para 2025. La compa帽铆a logr贸 $10.7M en ingresos netos en el tercer trimestre y report贸 un Valor Neto de Activos no auditado de $127.5M al 28 de enero de 2025. Su subsidiaria Hydreight Technologies ocup贸 el puesto #56 en la lista 2024 de Deloitte Technology Fast 500, alcanz贸 la rentabilidad y lanz贸 un programa de Acelerador de Salud de $10M.
La plataforma VSDHOne de la compa帽铆a ahora impulsa marcas de atenci贸n m茅dica en los 50 estados de EE. UU., ofreciendo soluciones de telemedicina y cumplimiento. Los desarrollos clave incluyen el trabajo de Insu Therapeutics en tecnolog铆a de entrega de insulina oral, la expansi贸n de Stardust Solar a Houston con una recaudaci贸n de $1.2M y los avances de EdgeTI en aplicaciones de computaci贸n cu谩ntica.
El portafolio de la compa帽铆a ha crecido de $4M en 2017 a aproximadamente $127M hoy, con inversiones totales de $13M en 25 empresas seleccionadas de m谩s de 1,000 evaluadas.
Victory Square Technologies電� 2024雲勳棎 雽頃� 欷戩殧頃� 靹标臣毳� 氤搓碃頃橁碃 2025雲� 鞝勲灥鞝� 牍勳爠鞚� 靹る獏頄堨姷雼堧嫟. 鞚� 須岇偓電� 3攵勱赴 靾滌澊鞚� $10.7M鞚� 雼劚頄堨溂氅� 2025雲� 1鞗� 28鞚� 旮办鞙茧 臧愳偓霅橃 鞎婌潃 靾滌瀽靷瓣皜旃橁皜 $127.5M鞚措澕瓿� 氤搓碃頄堨姷雼堧嫟. 鞛愴殞靷� Hydreight Technologies電� 2024雲� Deloitte Technology Fast 500鞐愳劀 56鞙勲ゼ 彀頃橁碃 靾橃澋鞚� 雼劚頄堨溂氅�, $10M鞚� 瓯搓皶 臧靻嶊赴 頂勲攴鸽灗鞚� 於滌嫓頄堨姷雼堧嫟.
须岇偓鞚� VSDHOne 頂岆灚韽�鞚 順勳灛 氙戈淡 50臧� 欤� 鞝勳棴鞐愳劀 鞚橂 敫岆灉霌滌棎 鞝勲牓鞚� 瓿店笁頃橂┌, 鞗愱博 鞚橂 氚� 欷靾� 靻旊(靺橃潉 鞝滉车頃╇媹雼�. 欤检殧 臧滊皽 靷暛鞙茧電� Insu Therapeutics鞚� 瓴疥惮 鞚胳姁毽� 鞝勲嫭 旮办垹 臧滊皽, Stardust Solar臧 頊挫姢韯挫棎 $1.2M鞚� 氇笀頃橃棳 頇曥灔頃橂姅 瓴�, EdgeTI鞚� 鞏戩瀽 旎错摠韺� 鞚戩毄 頂勲攴鸽灗 氚滌爠 霌膘澊 鞛堨姷雼堧嫟.
须岇偓鞚� 韽姼韽措Μ鞓る姅 2017雲� $4M鞐愳劀 鞓る姌 雽霝� $127M鞙茧 靹膘灔頄堨溂氅�, 1,000臧� 鞚挫儊鞚� 韽夑皜霅� 旮办梾 欷戩棎靹� 靹犿儩霅� 25臧� 旮办梾鞐� 齑� $13M鞚� 韴瀽毳� 旮半頄堨姷雼堧嫟.
Victory Square Technologies a rapport茅 des r茅alisations significatives pour 2024 et a esquiss茅 sa vision strat茅gique pour 2025. L'entreprise a r茅alis茅 10,7 millions de dollars de b茅n茅fice net au T3 et a d茅clar茅 une valeur nette d'actifs non v茅rifi茅e de 127,5 millions de dollars au 28 janvier 2025. Sa filiale Hydreight Technologies a 茅t茅 class茅e #56 dans le classement 2024 Deloitte Technology Fast 500, a atteint la rentabilit茅 et a lanc茅 un programme d'acc茅l茅rateur de sant茅 de 10 millions de dollars.
La plateforme VSDHOne de l'entreprise alimente d茅sormais des marques de sant茅 dans les 50 脡tats am茅ricains, offrant des solutions de t茅l茅m茅decine et de conformit茅. Parmi les d茅veloppements cl茅s, on trouve le travail d'Insu Therapeutics sur la technologie de d茅livrance d'insuline orale, l'expansion de Stardust Solar 脿 Houston avec une lev茅e de fonds de 1,2 million de dollars, et l'avancement d'EdgeTI dans les applications de calcul quantique.
Le portefeuille de l'entreprise est pass茅 de 4 millions de dollars en 2017 脿 environ 127 millions de dollars aujourd'hui, avec des investissements totalisant 13 millions de dollars dans 25 entreprises s茅lectionn茅es parmi plus de 1 000 茅valu茅es.
Victory Square Technologies berichtete 眉ber bedeutende Erfolge f眉r 2024 und skizzierte seine strategische Vision f眉r 2025. Das Unternehmen erzielte 10,7 Millionen Dollar Nettogewinn im 3. Quartal und meldete zum 28. Januar 2025 einen nicht gepr眉ften Nettoverm枚genswert von 127,5 Millionen Dollar. Ihre Tochtergesellschaft Hydreight Technologies belegte den 56. Platz im Deloitte Technology Fast 500 f眉r 2024, erzielte Rentabilit盲t und startete ein Gesundheitsbeschleunigungsprogramm im Wert von 10 Millionen Dollar.
Die VSDHOne Plattform des Unternehmens unterst眉tzt jetzt Gesundheitsmarken in allen 50 Bundesstaaten der USA und bietet Telemedizin- und Compliance-L枚sungen an. Zu den Hauptentwicklungen geh枚ren die Arbeit von Insu Therapeutics an der Technologie zur oralen Insulindelivierung, die Expansion von Stardust Solar nach Houston mit einer Kapitalerh枚hung von 1,2 Millionen Dollar und die Fortschritte von EdgeTI bei Anwendungen der Quantencomputing.
Das Portfolio des Unternehmens ist von 4 Millionen Dollar im Jahr 2017 auf etwa 127 Millionen Dollar heute gewachsen, mit insgesamt 13 Millionen Dollar an Investitionen in 25 Unternehmen, die aus 眉ber 1.000 bewerteten ausgew盲hlt wurden.
- Q3 2024 net income of $10.7M with EPS of $0.11
- Hydreight Technologies achieved profitability in 2024
- Portfolio value growth from $4M in 2017 to $127M in 2025
- Hydreight's network expansion to 2,500+ nurses and 100+ doctors across all 50 states
- Successful $1.2M fundraise for Stardust Solar
- None.
- Significant Net Income Growth: Victory Square achieved
$10.7M in Q3 net income - Unaudited Net Asset Value (NAV): Estimated at
$127,524,464 * as of January 28, 2025 (see Use of Non-GAAP Financial Measures). - Digital Health Expansion: The VSDHOne platform powers healthcare brands across all 50 U.S. states, offering telehealth, compliance solutions, and direct-to-consumer scalability.
- Hydreight Technologies' Milestones: Hydreight ranked #56 on the 2024 Deloitte Technology Fast 500™, achieved profitability in 2024, and launched a
$10M Health Accelerator to foster the next generation of digital health entrepreneurs. - Diabetes Care Advancements: Insu Therapeutics is developing oral delivery technology for insulin and peptide-based drugs, targeting the
$118B global diabetes market. - Sustainability in Action: Stardust Solar expands into Houston,, and raises
$1.2M to support renewable energy initiatives. - Frontier Technologies: EdgeTI advances quantum computing applications, while XR Immersive integrates continuous glucose monitoring (CGM) technology for enhanced diabetes management.
- 2025 Vision: Strategic focus on scaling digital health solutions, accelerating portfolio growth, and enhancing shareholder value.
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2025) - Victory Square Technologies Inc. (CSE: VST) (OTCQB: VSQTF) (FSE: 6F6) ("Victory Square" or the "Company") is a venture builder that provides investors with access to a diversified portfolio of 25+ high-growth companies in digital health, renewable energy, artificial intelligence, and more-all within a single stock. The company identifies and scales transformative technologies, driving long-term shareholder value. The Company is pleased to provide its latest Corporate Update. The report highlights significant milestones achieved in 2024 and strategic priorities aimed at driving innovation and shareholder value in 2025.
To Our Valued Shareholders,
As we enter 2025, Victory Square Technologies (VST) remains focused on advancing digital health and driving meaningful innovation. The healthcare sector is undergoing significant transformation, influenced by rising costs, an aging population, and rapid technological advancements.
Digital health presents a major opportunity to enhance accessibility, efficiency, and patient outcomes. As Marc Andreessen noted, "Healthcare is undergoing a software revolution." VST is committed to leveraging this shift to develop scalable, patient-centric solutions that create long-term value for both the healthcare industry and our shareholders.
Hydreight Technologies: Scaling Direct-to-Consumer Healthcare
Hydreight Technologies (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) continues to demonstrate strong growth and industry impact:
- Deloitte Technology Fast 500™ Recognition: Ranked #56, with a three-year revenue compound annual growth rate (CAGR) of
54% . (Source: ) - Expanding Provider Network: Over 2,500 nurses, 100 doctors, and a 503B pharmacy network covering all 50 U.S. states.
- Achieved Profitability in 2024: A milestone reflecting operational efficiency, market leadership, and a scalable business model. (Source: )
$10M Health Accelerator Program: In partnership with Victory Square, Hydreight is investing in early-stage digital health companies using the VSDHOne platform to enable scalable growth. (Source: )- Expanded Telehealth Offerings: New services include GLP-1 medications, genetic testing, and hormone replacement therapy, addressing a broad range of patient needs.
- Launch of VSDHOne: Strengthening digital health infrastructure and supporting business growth across multiple healthcare sectors.
Strategic Partnership: Hydreight and The DRIPBaR
Hydreight Technologies has partnered with The DRIPBaR to launch 'DRIPBaR Direct,' a nationwide direct-to-consumer healthcare initiative powered by the VSDHOne platform. This collaboration enables The DRIPBaR to offer seamless telehealth consultations and physician-prescribed wellness treatments across the country, leveraging a compliant infrastructure and competitive pricing models comparable to established brands like HIMS. (Source: )
Portfolio Expansion Beyond Digital Health
Insu Therapeutics:
- University of British Columbia (UBC) spinoff developing oral drug delivery technologies for diabetes care.
- Targeting the
$118B global diabetes drug market, addressing a growing patient population of over 783 million individuals. - Advancing regulatory approvals with FDA and EMA for innovative peptide-based treatments.
Stardust Solar (TSXV: SUN):
- Expanded U.S. operations with a Houston franchise launch. (Source: )
- Partnered with Tesla to accelerate renewable energy adoption. (Source: )
- Raised
$1.2M in an oversubscribed private placement. (Source: )
Edge Total Intelligence (TSXV: CTRL):
- Developing quantum computing applications and digital twin technology. (Source: )
- Secured C
$5M in private placement financing for product development. (Source: )
XR Immersive Technologies (CSE: VRAI):
- Acquired InsulinQ's CGM technology to enhance diabetes management solutions. (Source: )
Financial Strength and Growth Outlook
- Q3 2024 Financial Results: Net income of
$10,661,274 and earnings per share of$0.11 , demonstrating strong execution and growth. - Unaudited Net Asset Value (NAV): Estimated at
$127,524,464 * as of January 28, 2025 (see Use of Non-GAAP Financial Measures).
"At Victory Square, we measure success through key performance indicators that reflect our growth: Cash Invested, Net Asset Value (NAV), Return on Invested Cash, Share Price/Market Cap vs. Index Benchmark, and Operating Costs as a % of NAV. Since 2017, we have evaluated over 1,000 companies, selecting 25 for investment. To date, we have invested
Strategic Focus: Digital Health & Expansion
Victory Square's continued emphasis on digital health is aligned with market demand for scalable, patient-centric healthcare solutions. Through Hydreight and VSDHOne, Victory Square is:
- Enabling Businesses to Scale: Providing a compliant telehealth infrastructure for nationwide expansion.
- Diversifying Healthcare Offerings: Supporting businesses in offering GLP-1 medications, lab testing, ED treatments, hair loss solutions, NAD therapy, genetic testing, and hormone replacement therapy.
- Accelerating Portfolio Growth: Strengthening partnerships and acquisitions to enhance revenue and market reach.
Looking Ahead: 2025 Growth Strategy
In 2025, Victory Square is focused on:
- Expanding Digital Health Infrastructure: Strengthening VSDHOne as a leading telehealth platform.
- Fueling Portfolio Growth: Supporting companies with capital and resources to scale efficiently.
- Enhancing Shareholder Value: Driving NAV growth and generating sustainable long-term returns.
"Victory Square is committed to advancing technology and healthcare solutions that improve accessibility and patient outcomes. Our 2024 results demonstrate our strategic execution, and we are focused on continuing this momentum into 2025 and beyond."
- Shafin Diamond Tejani, Chairman and CEO, Victory Square Technologies
Join Us in 2025
Victory Square invites investors, partners, and stakeholders to be part of its journey in shaping the future of digital health and technology-driven innovation.
For further information about Victory Square, please contact:
Investor Relations Contact - Abbey Vogt
Email: [email protected]
Telephone: 604 283-9166
Peter Smyrniotis - Director
Telephone: 604 283-9166
*Use of Non-GAAP Financial Measures:
This release contains references to NAV which is a non-GAAP financial measure. NAV is calculated as the value of total assets. The term NAV does not have any standardized meaning according to GAAP and therefore may not be comparable to similar measures presented by other companies. There is no comparable GAAP financial measure presented in Victory Square Technologies Inc. consolidated financial statements and thus no applicable quantitative reconciliation for such non-GAAP financial measure. The Company believes that the measure provides information useful to its shareholders in understanding the Company's performance, and may assist in the evaluation of the Company's business relative to that of its peers. This data is furnished to provide additional information and does not have any standardized meaning prescribed by GAAP. Accordingly, it should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP, and is not necessarily indicative of other metrics presented in accordance with GAAP. Existing NAV of the Company is not necessarily predictive of the Company's future performance or the NAV of the Company as at any future date.
About Victory Square Technologies Inc.
Victory Square is a Venture Builder that offers investors a liquid way to invest in early-stage technology companies without requiring accredited investor status or long-term commitments typically associated with venture funds.
- A diverse portfolio of 25+ innovative companies from around the world (founders hail from Ireland, Sri Lanka, Bulgaria, Australia, India, Brazil, the Middle East, and North America)
- Sectors include: Digital Health, Artificial Intelligence (AI), Machine Learning (ML), Web3, Virtual & Augmented AG真人官方ity (VR/AR), Gaming, Climate Tech
- Owner-operated (approx.
15% Management Ownership)
Business Model:
Victory Square's business model focuses on buying, building, and investing in early-stage tech companies. We dedicate up to 48 months with these companies to help them grow and become ready to spin-off or stand on their own. Some unique elements of our approach include:
- Unparalleled Access: Through our internal incubator and international network, we connect with over 250 founders, investors, tech accelerators, and venture capital firms from more than 60 countries.
- Active Involvement: Our management team and advisors provide financial, operational, and strategic support to scale companies globally-from incubation to monetization.
- Reinvestment Strategy: We drive value by monetizing investments and reinvesting the gains into new innovations, ensuring that our business remains self-sustaining.
Victory Square Technologies is publicly traded, headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6), and OTCQX (VSQTF).
For more information, visit .
ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.
FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the outlook of the business of Victory Square and its portfolio companies, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries and portfolio companies, including those items listed under the heading "Net Asset Value ("NAV") Update", "Notable Portfolio Highlights" and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as "believes", "expects", "to be", "anticipates", "estimates", "intends", "plans", "continues", "project", "potential", "possible", "contemplate", "seek", "goal", "objectives", "outlook" or similar expressions, or may employ such future or conditional verbs as "may", "might", "will", "could", "should" or "would", or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Although Victory Square believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statements has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Victory Square's control, including, but not limited to, the risk factors discussed in the continuous disclosure materials of the Victory Square which are available under the Victory Square's profile on SEDAR at www.sedar.com. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
To view the source version of this press release, please visit